Are Non-Steroidal Anti-Inflammatory Drugs Effective for the Management

Total Page:16

File Type:pdf, Size:1020Kb

Are Non-Steroidal Anti-Inflammatory Drugs Effective for the Management Eur Spine J DOI 10.1007/s00586-015-3891-4 REVIEW ARTICLE Are non-steroidal anti-inflammatory drugs effective for the management of neck pain and associated disorders, whiplash-associated disorders, or non-specific low back pain? A systematic review of systematic reviews by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration 1,2,3 1,4 5 1,6 Jessica J. Wong • Pierre Coˆte´ • Arthur Ameis • Sharanya Varatharajan • 1,7 1,6 8,9 Thepikaa Varatharajan • Heather M. Shearer • Robert J. Brison • 1,6 1,6 1,6 1,10 Deborah Sutton • Kristi Randhawa • Hainan Yu • Danielle Southerst • 4 4,6 1 11 Rachel Goldgrub • Silvano Mior • Maja Stupar • Linda J. Carroll • Anne Taylor-Vaisey1 Received: 5 November 2014 / Revised: 18 March 2015 / Accepted: 19 March 2015 Ó Springer-Verlag Berlin Heidelberg 2015 Abstract included systematic reviews with a low risk of bias in our Purpose To evaluate the effectiveness of non-steroidal best evidence synthesis. anti-inflammatory drugs (NSAIDs) for the management of Results We screened 706 citations and 14 systematic re- neck pain and associated disorders (NAD), whiplash-as- views were eligible for critical appraisal. Eight systematic sociated disorders, and non-specific low back pain (LBP) reviews had a low risk of bias. For recent-onset NAD, with or without radiculopathy. evidence suggests that intramuscular NSAIDs lead to Methods We systematically searched six databases from similar outcomes as combined manipulation and soft tissue 2000 to 2014. Random pairs of independent reviewers therapy. For NAD (duration not specified), oral NSAIDs critically appraised eligible systematic reviews using the may be more effective than placebo. For recent-onset LBP, Scottish Intercollegiate Guidelines Network criteria. We evidence suggests that: (1) oral NSAIDs lead to similar outcomes to placebo or a muscle relaxant; and (2) oral NSAIDs with bed rest lead to similar outcomes as placebo Systematic Review Registration Number: CRD42014009782. & Jessica J. Wong 6 Graduate Education and Research Programs, Canadian [email protected] Memorial Chiropractic College (CMCC), 6100 Leslie Street, Toronto, ON M2H 3J1, Canada 1 UOIT-CMCC Centre for the Study of Disability Prevention 7 and Rehabilitation, University of Ontario Institute of Graduate Studies in Masters of Public Health, University of Technology (UOIT) and Canadian Memorial Chiropractic Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 5E5, College (CMCC), 6100 Leslie Street, Toronto, ON M2H 3J1, Canada Canada 8 Kingston General Hospital, 76 Stuart Street, Kingston, 2 Undergraduate Education, Canadian Memorial Chiropractic ON K7L 2V7, Canada College, 6100 Leslie Street, Toronto, ON M2H 3J1, Canada 9 Department of Emergency Medicine, School of Medicine, 3 Division of Graduate Studies, Canadian Memorial Queen’s University, Kingston, ON, Canada Chiropractic College, 6100 Leslie Street, Toronto, 10 Rebecca MacDonald Centre for Arthritis and Autoimmune ON M2H 3J1, Canada Disease, Mount Sinai Hospital, Joseph and Wolf Lebovic 4 Faculty of Health Sciences, University of Ontario Institute of Health Complex, 60 Murray Street, 2nd Floor (Main), Technology (UOIT), 2000 Simcoe Street North, Oshawa, Toronto, ON M5T 3L9, Canada ON L1H 7L7, Canada 11 Injury Prevention Centre, University of Alberta, 4075 RTF, 5 Certification Program in Insurance Medicine and Medico- 8308 114 Street, Edmonton T6G 2E1, AB, Canada legal Expertise, Faculty of Medicine, University of Montreal, N-414, Roger-Gaudry Building, 2900, Boulevard Edouard- Montpetit, Montreal, QC H3T 1J4, Canada 123 Eur Spine J with bed rest. For persistent LBP, evidence suggests that: low back pain [25, 26]. For lumbar radiculopathy, two (1) oral NSAIDs are more effective than placebo; and (2) systematic reviews reported that NSAIDs are not more oral NSAIDs may be more effective than acetaminophen. effective than placebo [27, 28]. For recent-onset LBP with radiculopathy, there is incon- Different methodologies used to conduct the previous sistent evidence on the effectiveness of oral NSAIDs versus reviews likely contributed to the differences in their con- placebo. Finally, different oral NSAIDs lead to similar clusions. The methodologies differed in the application of outcomes for neck and LBP with or without radiculopathy. critical appraisal and evidence synthesis methods. Across Conclusions For NAD, oral NSAIDs may be more ef- reviews, different instruments were used to critically ap- fective than placebo. Oral NSAIDs are more effective than praise the literature and synthesize the evidence [21–28]. placebo for persistent LBP, but not for recent-onset LBP. Inclusion of studies with a high risk of bias may threaten Different oral NSAIDs lead to similar outcomes for neck the internal validity of a systematic review. Randomized pain and LBP. controlled trials (RCTs) with poor internal validity were used in the evidence synthesis of six reviews [21, 25, 26, Keywords Whiplash-associated disorders Á Neck pain 29–31]. Considering the varying methodologies used in and associated disorders Á Nonspecific low back pain Á previous systematic reviews, an in-depth review of their Nonsteroidal anti-inflammatory drugs Á Systematic review Á quality is warranted prior to accepting their results. Medication We conducted a systematic review of systematic re- views to examine the effectiveness of NSAIDs for the management of neck pain and associated disorders (NAD), Introduction whiplash-associated disorders (WAD), or non-specific low back pain with or without radiculopathy. Neck and back pain are experienced by more than 80 % of the population during their lifetime, and are common rea- sons for seeking healthcare [1–6]. These conditions are Methods costly, and work absenteeism and lost productivity are frequent complications [7–9]. Most neck and back pain are Registration common sources of disability, whether attributed to work, traffic collision, or daily activities [1, 3, 10–13]. To date, We registered our protocol with the International few interventions demonstrate efficacy on a scientifically Prospective Register of Systematic Reviews (PROSPERO) valid basis and most interventions are only associated with on May 14, 2014 (CRD42014009782). short-term benefits [14, 15]. Non-steroidal anti-inflammatory drugs (NSAIDs) are Eligibility criteria commonly used for neck and low back pain. NSAIDs suppress inflammatory processes that produce swelling and Population pain [16]. In the United States, NSAIDs are the most common intervention prescribed for non-malignant chronic Our review targeted systematic reviews of adults or chil- pain, including musculoskeletal disorders, with use re- dren with NAD or WAD (grades I–III), or non-specific low ported in approximately 95 % of visits to physicians [17]. back pain (with or without radiculopathy) and excluded In the United Kingdom, general practitioners prescribed pain from major pathology (fractures, dislocations, spinal NSAIDs to approximately 30 % of patients with chronic cord injury, infection, neoplasms, systemic disease). We low back pain [18]. In Spain, 41 % of patients with low defined NAD and WAD according to previous classifica- back pain reported taking NSAIDs for more than 1 month tions [32, 33] (Table 1). We defined non-specific low back in the past year [19]. pain as low back pain with or without radiculopathy in the Despite its common use, the effectiveness of NSAIDs absence of specific pathological entities [24]. for the management of neck and low back pain is not firmly established [20–22]. Several systematic reviews examining Intervention NSAIDs for neck and low back pain have reported limited or unclear evidence [20–22]. In contrast, two systematic We restricted our review to systematic reviews that tested reviews concluded (based on low quality evidence and the effectiveness of NSAIDs. NSAIDs are defined as small effect sizes) that NSAIDs are effective for short-term medications that block the action of cyclo-oxygenase symptomatic relief in patients with low back pain [23, 24]. (Cox)-1 and/or Cox-2 (necessary for prostaglandin pro- Furthermore, two reviews found evidence supporting the duction), thus reducing inflammation and pain [16]. Cox-1 use of NSAIDs in individuals with acute [25] or chronic enzymes are also cyto-protective; blocking their action is 123 Eur Spine J Table 1 Classification of grades for neck pain and associated dis- systematic review of studies (with or without meta-analy- orders [32] and whiplash-associated disorders [33] sis); and (4) adults or children with NAD, WAD, or non- Grade Definition specific low back pain with or without radiculopathy (mixed populations must have stratified results for NAD, Neck pain and associated disorders WAD, or non-specific low back pain). I No signs or symptoms suggestive of major structural We excluded: (1) guidelines, letters, editorials, com- pathology and no or minor interference with activities of daily living mentaries, unpublished manuscripts, dissertations, govern- II No signs or symptoms of major structural pathology, ment reports, books, conference proceedings, meeting but major interference with activities of daily living abstracts, lectures and addresses, consensus development III No signs or symptoms of major structural pathology, but statements; (2) non-systematic reviews, RCTs, cohort presence of neurologic signs such as decreased deep tendon studies, case–control studies, cross-sectional studies, case reflexes, weakness or sensory deficits reports/series, qualitative studies, biomechanical studies, a IV Signs or symptoms of major
Recommended publications
  • United States Patent (19) 11 Patent Number: 5,955,504 Wechter Et Al
    USOO5955504A United States Patent (19) 11 Patent Number: 5,955,504 Wechter et al. (45) Date of Patent: Sep. 21, 1999 54 COLORECTAL CHEMOPROTECTIVE Marnett, “Aspirin and the Potential Role of Prostaglandins COMPOSITION AND METHOD OF in Colon Cancer, Cancer Research, 1992; 52:5575–89. PREVENTING COLORECTAL CANCER Welberg et al., “Proliferation Rate of Colonic Mucosa in Normal Subjects and Patients with Colonic Neoplasms: A 75 Inventors: William J. Wechter; John D. Refined Immunohistochemical Method.” J. Clin Pathol, McCracken, both of Redlands, Calif. 1990; 43:453-456. Thun et al., “Aspirin Use and Reduced Risk of Fatal Colon 73 Assignee: Loma Linda University Medical Cancer." N Engl J Med 1991; 325:1593-6. Center, Loma Linda, Calif. Peleg, et al., “Aspirin and Nonsteroidal Anti-inflammatory Drug Use and the Risk of Subsequent Colorectal Cancer.” 21 Appl. No.: 08/402,797 Arch Intern Med. 1994, 154:394–399. 22 Filed: Mar 13, 1995 Gridley, et al., “Incidence of Cancer among Patients With Rheumatoid Arthritis J. Natl Cancer Inst 1993 85:307-311. 51) Int. Cl. .......................... A61K 31/19; A61K 31/40; Labayle, et al., “Sulindac Causes Regression Of Rectal A61K 31/42 Polyps. In Familial Adenomatous Polyposis” Gastroenterol 52 U.S. Cl. .......................... 514/568; 514/569; 514/428; ogy 1991 101:635-639. 514/416; 514/375 Rigau, et al., “Effects Of Long-Term Sulindac Therapy On 58 Field of Search ..................................... 514/568, 570, Colonic Polyposis” Annals of Internal Medicine 1991 514/569, 428, 416, 375 11.5:952-954. Giardiello.et al., “Treatment Of Colonic and Rectal 56) References Cited Adenomas With Sulindac In Familial Adenomatous Poly U.S.
    [Show full text]
  • Universitätsspital Balgrist, Zürich Chiropraktische Medizin Kommissarischer Leiter: Prof
    Universitätsspital Balgrist, Zürich Chiropraktische Medizin Kommissarischer Leiter: Prof. Dr. Armin Curt, MD, FRCPC Betreuung der Masterarbeit: Dr. Brigitte Wirth, PT, PhD Leitung der Masterarbeit: Prof. em. Dr. Barry Kim Humphreys, BSc, DC, PhD A SYSTEMATIC REVIEW ON QUANTIFIABLE PHYSICAL RISK FACTORS FOR NON-SPECIFIC ADOLESCENT LOW BACK PAIN MASTERARBEIT zur Erlangung des akademischen Grades Master in Chiropraktischer Medizin (M Chiro Med) der Medizinischen Fakultät der Universität Zürich vorgelegt von Tobias Potthoff (09-712-712) 2017 Table of Content 1. Scientific Accompanying Text .......................................................................................................... 3 2. Abstract ......................................................................................................................................... 13 3. Introduction ................................................................................................................................... 14 4. Methods ........................................................................................................................................ 15 a. Search strategy .......................................................................................................................... 15 b. Inclusion criteria ........................................................................................................................ 15 c. Study selection .........................................................................................................................
    [Show full text]
  • Solid Solution Compositions and Use in Chronic Inflammation
    (19) *EP003578172A1* (11) EP 3 578 172 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.12.2019 Bulletin 2019/50 A61K 9/14 (2006.01) A61K 47/14 (2017.01) A61K 47/44 (2017.01) A61K 31/12 (2006.01) (2006.01) (2006.01) (21) Application number: 19188174.7 A61K 31/137 A61K 31/167 A61K 31/192 (2006.01) A61K 31/216 (2006.01) (2006.01) (2006.01) (22) Date of filing: 14.01.2014 A61K 31/357 A61K 31/366 A61K 31/4178 (2006.01) A61K 31/4184 (2006.01) A61K 31/522 (2006.01) A61K 31/616 (2006.01) A61K 31/196 (2006.01) (84) Designated Contracting States: • BREW, John AL AT BE BG CH CY CZ DE DK EE ES FI FR GB London, Greater London EC2Y 8AD (GB) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • REILEY, Richard Robert PL PT RO RS SE SI SK SM TR London, Greater London EC2Y 8AD (GB) • CAPARRÓS-WANDERLEY, Wilson (30) Priority: 14.01.2013 US 201361752356 P London, Greater London EC2Y 8AD (GB) 04.02.2013 US 201361752309 P (74) Representative: Clements, Andrew Russell Niel et (62) Document number(s) of the earlier application(s) in al accordance with Art. 76 EPC: Schlich 14702460.8 / 2 925 367 9 St Catherine’s Road Littlehampton, West Sussex BN17 5HS (GB) (71) Applicant: InFirst Healthcare Limited London EC2Y 8AD (GB) Remarks: This application was filed on 24-07-2019 as a (72) Inventors: divisional application to the application mentioned • BANNISTER, Robin Mark under INID code 62.
    [Show full text]
  • Injuries and Affections of the Spine ศ.นพ.พิบูลย์ อิทธิระวิวงศ์ ภาควิชาออร์โธปิดิกส์ I
    Injuries and Affections of the Spine ศ.นพ.พิบูลย์ อิทธิระวิวงศ์ ภาควิชาออร์โธปิดิกส์ I. Injuries of the spine and thorax :- Classification 1. Major fractures and displacements of the cervical spine - Wedge compression fracture of vertebral body - Burst fracture of vertebral body - Extension subluxation - Flexion subluxation - Dislocation and fracture-dislocation - Fracture of the aieas - Fracture-dislocation of atlanto-axial joint - Intra-spinal displacements of soft tissue 2. Major fractures and displacements of the thoracic and lumbar vertebrae - Wedge compression fracture of vertebral body - Burst fracture of vertebral body - Dislocation and fracture-dislocation 3. Paraplegia from spinal injuries 4. Minor fractures of the spinal column - Fracture of transverse processes - Fracture of spinous processes - Fracture of the sacrum - Fracture of the coccyx 5. Fractures of the thoracic case - Fracture of the ribs - Fracture of the sternum II. Orthopaedic disorders of the spine Disorders Neck and cervical spine Trunk and spine (T,L,S) Congenital - Lumbar and sacral variations, abnormalities Hemivertebra. Spina bifida. Deformities Infantile torticollis Scoliosis. Congenital short neck Kyphosis. Congenital high spcapula Lordosis. Infections of bone Tuberculosis of C-spine Tuberculosis of T or L-spine Pyogenic infection of C- Pyogenic infection of T of L-spine. spine Arthritis of the spinal Ankylosing spondylitis Rheumatoid arthritis Osteoarthritis joints Cervical spondylosis Ankylosing spondylitis Osteochondritis - Scheuermann’s disease Calve’s
    [Show full text]
  • Evicore Spine Imaging Guidelines
    CLINICAL GUIDELINES Spine Imaging Policy Version 1.0 Effective February 14, 2020 eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual’s Primary Care Physician (PCP) may provide additional insight. CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein. © 2019 eviCore healthcare. All rights reserved. Spine Imaging Guidelines V1.0 Spine Imaging Guidelines Procedure Codes Associated with Spine Imaging 3 SP-1: General Guidelines 5 SP-2: Imaging Techniques 14 SP-3: Neck (Cervical Spine) Pain Without/With Neurological Features (Including Stenosis) and Trauma 22 SP-4: Upper Back (Thoracic Spine) Pain Without/With Neurological Features (Including Stenosis) and Trauma 26 SP-5: Low Back (Lumbar Spine) Pain/Coccydynia without Neurological Features 28 SP-6: Lower Extremity Pain with Neurological Features (Radiculopathy, Radiculitis, or Plexopathy and Neuropathy) With or Without Low Back (Lumbar Spine) Pain 32 SP-7: Myelopathy 36 SP-8: Lumbar Spine Spondylolysis/Spondylolisthesis 39 SP-9: Lumbar Spinal Stenosis 42 SP-10: Sacro-Iliac (SI) Joint Pain, Inflammatory Spondylitis/Sacroiliitis and Fibromyalgia 44 SP-11: Pathological Spinal Compression Fractures 47 SP-12: Spinal Pain in Cancer Patients 49 SP-13: Spinal Canal/Cord Disorders (e.g.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub
    US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs Inhibit Bone Healing: a Review S
    Review Article © Schattauer 2010 385 Non-steroidal anti-inflammatory drugs inhibit bone healing: A review S. Barry Washington State University, Department of Veterinary Clinical Sciences, Veterinary Teaching Hospital, Pullman, Wash- ington, USA crine and autocrine activity, have since Keywords stems from prostaglandin inhibition and is been shown to regulate constitutive and in- Non-steroidal anti-inflammatory drugs, likely multifactorial. In human medicine ducible functions throughout the body, in- NSAID, bone healing NSAID are known to prevent heterotopic ossi- cluding bone healing (5–9). The mech- fication, however the clinical importance of anism of NSAID inhibition to bone healing Summary their effects on bone healing remains contro- is unknown, but is likely multifactorial. Re- The ability of non-steroidal anti-inflammatory versial. Although a small handful of reports searchers have suggested that NSAID affect drugs (NSAID) to inhibit bone healing has suggest that NSAID suppress bone healing in normal bone healing in multiple ways, with been established in experimental animal dogs and horses, there is little published infor- emphasis often (but not exclusively) placed models using mice, rats, and rabbits. The mation to direct veterinary practice in do- on processes related to the inflammatory mechanism of action is largely unknown but mestic species. stage. Deciphering the mechanism of NSAID inhibition requires an understanding of Correspondence to: Vet Comp Orthop Traumatol 2010; 23: 385–392 Sabrina Barry, DVM doi:10.3415/VCOT-10-01-0017 fracture healing. Fracture healing presents Washington State University Received: January 31, 2010 an exquisitely orchestrated series of coor- Department of Veterinary Clinical Sciences Accepted: June 23, 2010 dinated molecular and cellular events.
    [Show full text]
  • Latest Administration Hour Prior to Competition Max Dosage Per Pound of Body Weight Medication Trade Name Medication Generic Name
    MEDICATION MEDICATION MAX DOSAGE PER POUND LATEST ADMINISTRATION HOUR ADMINISTRATION METHOD GENERIC NAME TRADE NAME OF BODY WEIGHT PRIOR TO COMPETITION (single dose per 24 hours unless specified otherwise) Dexamethasone Azium® 2.0 mg/100Lb >12 hours IV, IM (20 mg/1000Lb) or 0.5 mg/100Lb >6 hours IV (5.0 mg/1000Lb) or 1.0 mg/100LB >6 hours Oral (10 mg/1000Lb) Diclofenac Surpass® 5 inch ribbon, 1⁄2 inch thick, >12 hours Topical, 2 doses each day 12 hours apart one site Firocoxib Equioxx® 0.1 mg/kg >12 hours Oral (0.0455 mg/Lb) (45.5 mg/1000Lb) Phenylbutazone (“bute”) * Butazolidin® 2.0 mg/Lb >12 hours Oral, IV (2.0 grams/1000Lb) or 1.0 mg/Lb AM & PM feed Oral, 2 doses each day, 12 hours apart (1.0 grams/1000Lb) Flunixin meglumine * Banamine® 0.5 mg/Lb >12 hours Oral, IV (500 mg/1000Lb) Ketoprofen Ketofen® 1.0 mg/Lb >4 hours, but IV (1.0 gram/1000Lb) >6 hours is recommended Meclofenamic acid Arquel® 0.5 mg/Lb Oral, 2 doses each day, 12 hours apart (500 mg/1000Lb) Naproxen Naprosyn® 4.0 mg/Lb >12 hours Oral (4.0 grams/1000Lb) Eltenac Not yet approved Telzenac® 0.25 mg/Lb (250 mg/1000Lb) 12 hours IV Methocarbamol Robaxin® 5.0 mg/Lb >6 hours Oral, IV, 2 doses each day, 12 hours apart (5.0 grams/1000Lb) * Do not administer phenylbutazone and flunixin at the same time (Unless used according to The maximum treatment time for any of the above permitted medication is five days, with the Section 8).
    [Show full text]
  • Simultaneous Determination of Residues of Non-Steroidal Anti-Inflammatory Drugs and Glucocorticosteroids in Animal Muscle By
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Food Anal. Methods (2016) 9:1837–1848 DOI 10.1007/s12161-015-0352-y Simultaneous Determination of Residues of Non-Steroidal Anti-Inflammatory Drugs and Glucocorticosteroids in Animal Muscle by Liquid Chromatography-Tandem Mass Spectrometry Piotr Jedziniak1 & Małgorzata Olejnik1 & Konrad Pietruk1 & Edyta Protasiuk1 & Teresa Szprengier-Juszkiewicz1 & Jan Żmudzki1 Received: 11 February 2015 /Accepted: 4 November 2015 /Published online: 21 November 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract A method for the determination of a wide range Introduction residues of anti-inflammatory drugs (16 acidic non-steroidal anti-inflammatory drugs and four metamizole metabolites and Non-steroidal anti-inflammatory drugs (NSAIDs) and five corticosteroids) has been was developed. In the first step glucocorticosteroids (GCs) are widely used in veterinary medi- of sample preparation, acetate buffer was added to minced cine as well as in treatment of diseases in food-producing ani- muscle samples and 15-min ultrasound-assisted enzymatic mals. Despite its effectiveness, the important drawback of phar- hydrolysis was performed. Next, the samples were extracted macotherapy is drug residues in animal tissues. It became an twice with acetonitrile, freezed and analysed. The analytes important issue in the food safety. Potential toxicity of medicinal were separated on a C18 column with a 25-min gradient of veterinary products has to be evaluated before the drug registra- methanol/acetonitrile (8:2) and 0.05 M ammonium formate at tion. When necessary, maximum residue limits (MRLs) in food pH 5.0 and determined by liquid chromatography-tandem are established.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Ige-Mediated Hypersensitivity to Lysine Clonixinate
    67 Practitioner's Corner IgE-Mediated Hypersensitivity to Lysine Clonixinate Villalón García AL, Pérez Pimiento A, López San Martín MG, Iglesias Cadarso A Allergy Department, University Hospital Puerta de Hierro, Madrid, Spain J Investig Allergol Clin Immunol 2021; Vol. 31(1): 67-68 doi: 10.18176/jiaci.0613 Key words: Lysine clonixinate. Drug allergy. Anti-inflammatory analgesics. Urticaria. IgE-mediated hypersensitivity. Palabras clave: Clonixinato de lisina. Alergia a medicamentos. Analgésicos antiinflamatorios. Urticaria. Hipersensibilidad mediada por IgE. Lysine clonixinate belongs to the nicotinic acid family, a family of nonsteroidal anti-inflammatory drugs (NSAIDs), which are in turn a class of antiprostaglandin drugs. At therapeutic doses, it acts mainly by inhibiting cyclooxygenase 2 (COX-2), whereas at lower doses, it inhibits cyclooxygenase 1 (COX-1). It is indicated as an analgesic and anti-inflammatory drug in patients with acute or chronic pain and has proven effective in various algic syndromes such as renal colic, nerve compression, muscular pain, and odontalgia [1]. It is generally administered orally, Figure. Skin prick test. although it is also effective and well tolerated intravenously for the treatment of severe migraine attacks [1-3]. Little is known about cross-reactivity between nicotinic acid family anti-inflammatory drugs (lysine clonixinate, morniflumate, to NSAIDs. Oral challenge with lysine clonixinate was not isonixin, and niflumic acid) in acute allergic reactions. Most performed. Skin prick testing with morniflumate, isonixin, are used as a useful alternative in patients with NSAID niflumic acid, and acetylsalicylic acid dissolved in saline was hypersensitivity [4]. Numerous studies compare the efficacy negative. Oral challenge with acetylsalicylic acid 1 g was well and tolerance profile of oral lysine clonixinate with that of tolerated.
    [Show full text]